---
title: "Lupin Wins FDA's Tentative Approval For Enzalutamide Tablets Across Multiple Strengths"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290977135.md"
description: "Lupin Ltd. received tentative FDA approval for its Enzalutamide Tablets (40 mg, 80 mg, 120 mg, and 160 mg). The agency approved the 40 mg and 80 mg strengths as bioequivalent to Astellas' Xtandi. Notably, Lupin's approval includes 120 mg and 160 mg strengths, offering new dosing alternatives for patients and healthcare providers."
datetime: "2026-06-26T13:59:06.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290977135.md)
  - [en](https://longbridge.com/en/news/290977135.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290977135.md)
---

# Lupin Wins FDA's Tentative Approval For Enzalutamide Tablets Across Multiple Strengths

Add  as your preferred news source on Google

 Add Now

Pharma major Lupin Ltd. announced (NSE: LUPIN) announced Friday that it has received tentative approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Enzalutamide Tablets, 40 mg, 80 mg, 120 mg, and 160 mg.

The FDA has tentatively approved Lupin's Enzalutamide Tablets, 40 mg and 80 mg as bioequivalent to reference listed drug (RLD) Xtandi Tablets of Astellas for the indication in the approved labeling.

While Xtandi Tablets are traditionally available in 40 mg and 80 mg strengths, Lupin's tentatively approved 120 mg and 160 mg strengths will provide healthcare providers and patients with alternative dosing options.

For comments and feedback contact: editorial@rttnews.com

Business News

### Related Stocks

- [ALPMY.US](https://longbridge.com/en/quote/ALPMY.US.md)
- [4503.JP](https://longbridge.com/en/quote/4503.JP.md)

## Related News & Research

- [Vir Biotechnology Q2 revenue up, beats estimates on Astellas payment](https://longbridge.com/en/news/295009203.md)
- [Astellas Pharma: Q1 delivered record revenue and profit growth, led by strategic brands and pipeline advances](https://longbridge.com/en/news/294920578.md)
- [AcuCort says phase IV real-world study finds higher patient satisfaction with Zeqmelit mouth film vs corticosteroid tablets](https://longbridge.com/en/news/295503711.md)
- [Consensus Cloud’s Corporate Engine Powers Solid Quarter](https://longbridge.com/en/news/295312090.md)
- [EXCLUSIVE: Scienture Launches Highest-Dose Naloxone Nasal Spray Rezenopy in US](https://longbridge.com/en/news/295661897.md)